European Commission approves Skyrizi (risankizumab) for the treatment of moderate to severe plaque psoriasis

AbbVie

30 April 2019 - Approval based on results from clinical studies showing high rates of skin clearance at 16 weeks; this clearance was durable at one year with every 12-week dosing.

AbbVie today announced that the European Commission has approved Skyrizi (risankizumab) for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy. Skyrizi (150 mg) is approved to be administered by two subcutaneous injections every 12 weeks following two initiation doses at week 0 and week 4. In clinical studies, Skyrizi demonstrated high rates of skin clearance at 16 weeks and this clearance was durable at one year (52 weeks).

This approval allows for the marketing of Skyrizi in all member states of the European Union, as well as Iceland, Liechtenstein and Norway.

Read AbbVie press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , Europe